✦ LIBER ✦

ACTIVE IMMUNOTHERAPY WITH B.C.G. FOR RECURRENT MALIGNANT MELANOMA

✍ Scribed by Gutterman, J.U; McBride, C; Freireich, E.J; Mavligit, G; Frei, E; Hersh, E.M

Book ID: 123027426
Publisher: The Lancet
Year: 1973
Tongue: English
Weight: 610 KB
Volume: 301
Category: Article
ISSN: 0140-6736
DOI: 10.1016/S0140-6736(73)90526-6

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

BCG immunotherapy for recurrent malignan

BCG immunotherapy for recurrent malignant melanoma

✍ Shelley L. Rasmussen; Jordan U. Gutterman; Evan M. Hersh; Sydney Boston; M. Mars 📂 Article 📅 1980 🏛 Springer-Verlag 🌐 English ⚖ 789 KB

A study was made of immunologic parameters obtained from patients with stage IIIB malignant melanoma who were treated with BCG. Patients with the longest disease-free interval and survival times were those who had small initial skin test reactions and developed larger reactions during the course of

Optimising immunotherapy for malignant m

Optimising immunotherapy for malignant melanoma

📂 Article 📅 2000 🏛 Adis International Limited (now part of Wolters Kl ⚖ 176 KB

Active specific immunotherapy for malign

Active specific immunotherapy for malignant melanoma with allogeneic melanoma vaccine dynamics of immunological parameters along with clinical response

✍ Tsukamoto, Hidekazu; Hayashibe, Kazuhito; Ichihashi, Masamitsu 📂 Article 📅 1993 🏛 Elsevier Science 🌐 English ⚖ 38 KB

Experimental trials of immunotherapy for

Experimental trials of immunotherapy for malignant melanoma

✍ Douglas Reintgen; Jeanne Becker; Hilliard F. Seigler 📂 Article 📅 1991 🏛 John Wiley and Sons 🌐 English ⚖ 809 KB

Conventional treatment for metastatic melanoma consists of surgical resection, chemotherapy, and radiation therapy. New approaches toward treatment of this disease include the development of passive and active immunotherapeutic regimens. Malignant melanoma is particularly amendable to immunotherapy

Immunotherapy for malignant melanoma: A

Immunotherapy for malignant melanoma: A review and update

✍ J. Michael C. Mcgee 📂 Article 📅 1991 🏛 John Wiley and Sons 🌐 English ⚖ 421 KB

Several different approaches to the application of specific active immunotherapy for the adjuvant therapy of melanoma have developed independently. Specific active immunotherapy refers to autologous or allogenic inoculation or transplantation of tumor cells or cell products into patients with cancer

Overview of melanoma vaccines: Active sp

Overview of melanoma vaccines: Active specific immunotherapy for melanoma patients

✍ David W. Ollila; Mark C. Kelley; Guy Gammon; Donald L. Morton 📂 Article 📅 1998 🏛 John Wiley and Sons 🌐 English ⚖ 96 KB 👁 2 views

Although a phase III trial has yet to show a statistically significant improvement in the disease-free or overall survival of melanoma patients receiving vaccine therapy, several phase II trials have shown enhanced disease-free and overall survival of patients who develop a humoral and/or cellular r